Canada markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
196.00-6.99 (-3.44%)
At close: 04:00PM EST
196.50 +0.50 (+0.26%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close202.99
Open195.56
Bid196.16 x 800
Ask196.50 x 1200
Day's Range194.61 - 206.24
52 Week Range90.29 - 464.00
Volume2,863,828
Avg. Volume3,340,642
Market Cap47.533B
Beta (5Y Monthly)-1.38
PE Ratio (TTM)6.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

    Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on average two months prior to officially receiving the designation Study introduces a new method of combining publicly available SARS-CoV-2 sequence information with predictive analytics to effectively detect and monitor potential high-risk variants which could help increase preparedness against future

  • GlobeNewswire

    BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

    Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTechBioNTech will hold exclusive worldwide development and commercialization rights to all immunotherapies arising from the collaborationCrescendo will receive $40 million upfront, including a cash payment and an equity investment from

  • Business Wire

    Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

    NEW YORK & MAINZ, Germany, January 05, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime. The collaboration builds on the companies’ success in developing the first appr